Clinical Trial Detail

NCT ID NCT03801434
Title Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Stanford University
Indications

hypereosinophilic syndrome

chronic eosinophilic leukemia

Therapies

Ruxolitinib

Age Groups: adult senior

Additional content available in CKB BOOST